Literature DB >> 28337366

Natural History of Early Gastric Cancer: a Case Report and Literature Review.

Tomohiro Iwai1, Masao Yoshida1, Hiroyuki Ono1, Naomi Kakushima1, Kohei Takizawa1, Masaki Tanaka1, Noboru Kawata1, Sayo Ito1, Kenichiro Imai1, Kinichi Hotta1, Hirotoshi Ishiwatari1, Hiroyuki Matsubayashi1.   

Abstract

Early detection and treatment decrease the mortality rate associated with gastric cancer (GC). However, the natural history of GC remains unclear. An 85-year-old woman was referred to our hospital for evaluation of a gastric tumor. Esophagogastroduodenoscopy identified a 6 mm, flat-elevated lesion at the lesser curvature of the antrum. A biopsy specimen showed a well-differentiated tubular adenocarcinoma. The depth of the lesion was estimated to be intramucosal. Although the lesion met the indications for endoscopic resection, periodic endoscopic follow-up was performed due to the patient's advanced age and comorbidities. The mucosal GC invaded into the submucosa 3 years later, and finally progressed to advanced cancer 5 years after the initial examination. The patient died of tumor hemorrhage 6.4 years after the initial examination. In this case, mucosal GC progressed to advanced GC, eventually leading to the patient's death from GC. Early and appropriate treatment is required to prevent GC-related death.

Entities:  

Keywords:  Early gastric cancer; Natural history

Year:  2017        PMID: 28337366      PMCID: PMC5362837          DOI: 10.5230/jgc.2017.17.e9

Source DB:  PubMed          Journal:  J Gastric Cancer        ISSN: 1598-1320            Impact factor:   3.720


INTRODUCTION

Gastric cancer (GC) accounts for 10% of all cancer-related deaths [1]. Although the reported 5-year overall survival rates in advanced GC range from 15% to 52% [23], those in early gastric cancer (EGC) range from 88% to 97% [45]. Early detection and treatment contribute to decreased mortality rates [6]. With the increased use of endoscopic treatment in EGC, the natural history of EGC must be considered in order to evaluate the efficacy of endoscopic resection and to improve treatment decision-making; this is particularly relevant for elderly patients. However, the chronological changes of GC, including whether mucosal GC can progress to advanced cancer, remain unclear due to a lack of follow-up with high-resolution endoscopic images [78910]. We present a case with prospective follow-up that provides a better understanding of the natural growth of GC.

CASE REPORT

An 85-year-old woman was referred to Shizuoka Cancer Center for evaluation of a gastric tumor in April 2007. Esophagogastroduodenoscopy (EGD) identified a 6 mm, flat-elevated lesion at the lesser curvature of the antrum. The lesion was diagnosed as Type 0-IIa EGC by endoscopy. The depth of the lesion was estimated to be intramucosal, because it was a flat-elevated lesion without nodules, remarkable depression, or fold convergence (Fig. 1A, B). Evaluation of a biopsy specimen revealed a well-differentiated tubular adenocarcinoma (Fig. 2A, B). Due to the patient's advanced age and comorbidities (rheumatoid arthritis and ischemic heart disease), she wished to receive periodic endoscopic follow-up and best supportive care without invasive treatment. Follow-up EGDs were performed at intervals of 6 months to 1 year.
Fig. 1

Chronological changes of the lesion. (A, B) A 6-mm, flat-elevated lesion at the lesser curvature of the antrum (Type 0-IIa, depth of tumor: mucosa). (C) Slight depression and small nodule was detected (Type 0-IIa+IIc, depth of tumor: submucosa). (D) The lesion sized up to 12 mm, and the depression became deeper (Type 0-IIa+IIc, depth of tumor: submucosa). (E) The lesion had enlarged, and ulceration was observed in the center of the lesion (Type 2, depth of tumor: muscularis propria). (F) The lesion invaded laterally, and the lesion enlarged to 50 mm with tumor oozing (Type 3, depth of tumor: subserosa). (G) The lesion became larger than 100 mm with severe stricture (Type 3, depth of tumor: serosa).

Fig. 2

Microscopic findings of the biopsy specimen. (A) Evaluation of a biopsy specimen showing a well differentiated tubular adenocarcinoma (H&E, bar length 500 μm). (B) Immunostaining with Ki-67 showing positive cells in all layers of the mucosa (Ki-67, bar length 500 μm). (C) Re-obtained biopsy specimen showing development of cytological and structural atypia in comparison with the initial examination (H&E, bar length 500 μm). (D) Immunostaining with Ki-67 showing positive cells in all layers of the mucosa and a higher rate of positive cells than the initial biopsy specimen (Ki-67, bar length 500 μm)

Chronological changes of the lesion. (A, B) A 6-mm, flat-elevated lesion at the lesser curvature of the antrum (Type 0-IIa, depth of tumor: mucosa). (C) Slight depression and small nodule was detected (Type 0-IIa+IIc, depth of tumor: submucosa). (D) The lesion sized up to 12 mm, and the depression became deeper (Type 0-IIa+IIc, depth of tumor: submucosa). (E) The lesion had enlarged, and ulceration was observed in the center of the lesion (Type 2, depth of tumor: muscularis propria). (F) The lesion invaded laterally, and the lesion enlarged to 50 mm with tumor oozing (Type 3, depth of tumor: subserosa). (G) The lesion became larger than 100 mm with severe stricture (Type 3, depth of tumor: serosa). Microscopic findings of the biopsy specimen. (A) Evaluation of a biopsy specimen showing a well differentiated tubular adenocarcinoma (H&E, bar length 500 μm). (B) Immunostaining with Ki-67 showing positive cells in all layers of the mucosa (Ki-67, bar length 500 μm). (C) Re-obtained biopsy specimen showing development of cytological and structural atypia in comparison with the initial examination (H&E, bar length 500 μm). (D) Immunostaining with Ki-67 showing positive cells in all layers of the mucosa and a higher rate of positive cells than the initial biopsy specimen (Ki-67, bar length 500 μm) From 2007 to 2009, the lesion showed no change in size or morphology. The estimated depth of the lesion remained within the mucosal layer. In order to reconfirm the initial diagnosis, a biopsy specimen was obtained from the lesion; it revealed a higher grade of cytological and structural atypia than the initial biopsy specimen (Fig. 2C, D). In 2010 and 2011, the follow-up EGD showed that the lesion had grown to 12 mm in size. It had also developed a slight depression and a 4 mm nodule, indicating submucosal invasion (Fig. 1C, D). In May 2012, further evaluation revealed that the lesion had an ulcer surrounded by a swollen gastric wall with clear margins. The macroscopic type was classified as Type 2 (Fig. 1E). The estimated depth of the Type 2 tumor was the muscularis propria. Six months later, the patient presented with symptoms of anemia, which was diagnosed as moderate anemia (hemoglobin 8.3 g/dL). EGD revealed oozing from the excavated ulcer of the tumor. The size of the lesion had increased to 50 mm. The advanced lesion invaded laterally without clear margins. The macroscopic type had progressed from Type 2 to Type 3. The depth of the lesion was estimated to extend to the subserosa (Fig. 1F). In 2013, the patient complained of insufficient food intake and symptoms of anemia. Her serum albumin and hemoglobin levels were 2.6 g/dL and 8.8 g/dL, respectively. The lesion had increased to more than 100 mm in size with severe stricture, which suggested tumor penetration of the serosa (Fig. 1G). That year, 6.6 years after the initial examination, the patient died of tumor hemorrhage. The Institutional Review Board of Shizuoka Cancer Center approved this case report (institutional code number: 25-J82-25-1-3).

DISCUSSION

The present case shows the natural history of EGC resulting in cancer-related death. At the initial examination, the lesion was classified as intramucosal cancer, and it remained in the early stage for at least 3.8 years. It could have been curatively treated by endoscopic submucosal dissection (ESD) until 2009 (2 years after the initial examination). Five years after the initial examination, the lesion finally progressed to advanced GC. The outcome may have been different if the patient had undergone ESD. In Japan, it has been reported that 87% of new lesions are detected in the early stage [1112], and 81% to 95% of these lesions meet the indications for ESD [45]. However, due to differences in the pathological diagnostic criteria for EGC between Japan and Western countries, EGC in Western countries, especially mucosal cancer, is often followed up as a pre-malignant lesion or pseudo-disease that is not expected to invade into the deeper layer [1013]. This case might represent a milestone in appreciating the importance of ESD for mucosal EGC. A review of the literature revealed two other case reports with prospective follow-up information (Table 1) [1415]. In both cases, the morphological type progressed from Type 0-IIc to Type 3. In the present case, the morphological type progressed to Type 3 via Type 0-IIa+IIc, comparable to the data in the previous reports. The duration of time in which the cancer remained within the mucosal layer after the initial examination was 3 years in one case and unknown in the other. In the present case, the cancer also remained within the mucosal layer for 3 years after the initial examination, which suggests that mucosal cancer has the potential to invade into the submucosal layer in approximately 3 years. A previous cohort study reported that the estimated median duration of the early stage disease was 3.7 years, and that the duration of the submucosal cancer was no more than 2 years [7]. Regarding the duration of the submucosal cancer, in the presented case and in one of the previous case reports, the duration was 2 years; this indicates that tumor growth may accelerate following submucosal invasion. One reported case was followed for 8 years and the patient died of other disease, while the other case was followed for 7.9 years and the patient underwent gastrectomy. To the best of our knowledge, there have been no reports of primary cases resulting in GC-related death with long-term observation. In the present case, EGC was the cause of death 6.4 years after the initial examination. A decision to treat EGC could be made if the average life expectancy of the patient is expected to be at least 5 years from the time of EGC diagnosis.
Table 1

Summary of reported cases presenting the natural history of early gastric cancer

VariableCase 1 [14]Case 2 [15]Present case
Age (yr)893785
SexMaleMaleFemale
Initial findingsLocationM, anterior wallU, lesser curvatureL, lesser curvature
Morphological type*Type 0-IIcType 0-IIcType 0-IIa
Size (mm)20Not known6
DepthMucosaMucosa or submucosaMucosa
Period of mucosal cancer (yr)3Not known3
Period of submucosal cancer (yr)2Not known2
Last findingsInterval (yr)87.96.4
Morphological type*Type 3Type 3Type 3
Size (mm)60Not known100
DepthSubserosa or serosaSubserosaSubserosa
OutcomeDeath from other diseaseAlive after gastrectomyDeath from gastric cancer

M = middle third of the stomach; U = upper third of the stomach; L = lower third of the stomach.

*Classification according to the Japanese Gastric Cancer Association guideline. †The time from the initial examination to the last examination.

M = middle third of the stomach; U = upper third of the stomach; L = lower third of the stomach. *Classification according to the Japanese Gastric Cancer Association guideline. †The time from the initial examination to the last examination. The present case and the literature review indicate that mucosal cancer can develop into submucosal invasive cancer, remain in the submucosal layer for about 2 years, and then invade into deeper layers. EGC should be treated appropriately, because it leads to cancer-related death even if the patient is elderly. The present case emphasizes the importance of early detection and appropriate treatment.
  15 in total

1.  Comparing mass screening techniques for gastric cancer in Japan.

Authors:  Atsushi Tashiro; Masatoshi Sano; Koichi Kinameri; Kazutaka Fujita; Yutaka Takeuchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

2.  Early gastric cancer: disease or pseudo-disease?

Authors:  S M Everett; A T Axon
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

3.  Validation of the new AJCC TNM staging system for gastric cancer in a large cohort of patients (n = 2,155): focus on the T category.

Authors:  A Marchet; S Mocellin; A Ambrosi; P Morgagni; G Vittimberga; F Roviello; D Marrelli; G de Manzoni; A Minicozzi; A Coniglio; G Tiberio; F Pacelli; F Rosa; D Nitti
Journal:  Eur J Surg Oncol       Date:  2011-07-02       Impact factor: 4.424

4.  Natural history of early gastric cancer: a non-concurrent, long term, follow up study.

Authors:  H Tsukuma; A Oshima; H Narahara; T Morii
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

5.  The long term outcome of gastric non-invasive neoplasia.

Authors:  M Rugge; M Cassaro; F Di Mario; G Leo; G Leandro; V M Russo; G Pennelli; F Farinati
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

6.  Gastric carcinoma resected 95 months after being diagnosed: report of a case.

Authors:  K Furukawa; K Yamada; K Konomi; M Tanaka
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Prospective study of "early" gastric cancer.

Authors:  H Tsukuma; T Mishima; A Oshima
Journal:  Int J Cancer       Date:  1983-04-15       Impact factor: 7.396

8.  Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study.

Authors:  H Isomoto; S Shikuwa; N Yamaguchi; E Fukuda; K Ikeda; H Nishiyama; K Ohnita; Y Mizuta; J Shiozawa; S Kohno
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

9.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.

Authors:  Atsushi Nashimoto; Kohei Akazawa; Yoh Isobe; Isao Miyashiro; Hitoshi Katai; Yasuhiro Kodera; Shunichi Tsujitani; Yasuyuki Seto; Hiroshi Furukawa; Ichiro Oda; Hiroyuki Ono; Satoshi Tanabe; Michio Kaminishi
Journal:  Gastric Cancer       Date:  2012-06-23       Impact factor: 7.370

10.  Natural history of gastric cancer-a case followed up for eight years: early to advanced gastric cancer.

Authors:  Junko Fujisaki; Toshifusa Nakajima; Toshiaki Hirasawa; Yorimasa Yamamoto; Akiyoshi Ishiyama; Tomohiro Tsuchida; Etsuo Hoshino; Masahiro Igarashi; Toshiharu Yamaguchi
Journal:  Clin J Gastroenterol       Date:  2012-07-29
View more
  2 in total

1.  Trends and Outcomes of Non-compliance with Treatment for Gastric Cancer in Korea over the 16 years from 1999 to 2015.

Authors:  Bang Wool Eom; Kyu-Won Jung; Young-Joo Won; Young-Woo Kim
Journal:  J Gastric Cancer       Date:  2019-02-20       Impact factor: 3.720

2.  Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study.

Authors:  Hsi-Lan Huang; Chi Yan Leung; Eiko Saito; Kota Katanoda; Chin Hur; Chung Yin Kong; Shuhei Nomura; Kenji Shibuya
Journal:  BMC Med       Date:  2020-09-14       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.